Method for producing cartilage tissue

Abstract

The present invention provides a method for producing a cartilage tissue, said method being characterized by comprising: a step for preparing a cell aggregate production substrate wherein, on a substrate capable of suppressing cell adhesion, a plurality of spots, said spots being formed of a copolymer that contains repeating units derived from monomers represented by formulae (I) and (II) [in the formulae, Ua1, Ua, Ra1, Ra2 and Rb are each as mentioned in the description and claims] are provided; a step for inoculating the substrate with PRRX1 protein-positive human cartilage precursor cells derived from pluripotent stem cells; a step for culturing the cells to form a cell aggregate; and a step for culturing the aggregate to form a cartilage tissue.

Description

[Technical Field]

[0001] The present invention relates to a method for producing a cartilage tissue structure. [Background technology]

[0002] One method of treating articular cartilage damage is the transplantation of autologous cultured cartilage tissue, which requires two surgeries: cartilage harvesting and cultured cartilage transplantation, placing a significant burden on the patient. To reduce this burden on patients, various regenerative medicine techniques have been proposed in which cartilage tissue for transplantation is produced not by autologous culture but by inducing the differentiation and culturing of various stem cells. For example, a technique has been reported in which induced pluripotent stem cells (iPS cells) are induced into mesoderm and cultured in the presence of ascorbic acid, BMP2, TGFβ, and GDF5, causing some of the cells on the dish to form chondrocyte aggregates, which are then detached and cultured in suspension to produce hyaline cartilage tissue (see, for example, Non-Patent Document 1). [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] A. Yamashita, M. Morioka, Y. Yahara, M. Okada, T. Kobayashi, S. Kuriyama, S. Matsuda, N. Tsumaki, Generation of scaffoldless hyaline cartilaginous tissue from human iPSCs, Stem cell reports 4 (2015) 404-418 Summary of the Invention [Problem to be solved by the invention]

[0004] While the above technology can produce hyaline cartilage tissue as the final product from human pluripotent stem cells, the intermediate stage cells (human chondroprogenitor cells) have not been defined. This has made it difficult to mass-produce cartilage regenerative materials with high efficiency and uniform tissue shape and properties. [Means for solving the problem]

[0005] The present inventors have conducted extensive research into intermediate-stage cells and methods for producing them when producing cartilage tissue from stem cells, as well as methods for producing cartilage tissue from those cells, and have even filed patent applications for some of these findings (see, for example, PCT / JP2020 / 035517). This method allows cells with intermediate differentiation propensity (i.e., chondroprogenitor cells) to be expanded and stocked, and quality-controlled cells from the same lot can be treated to induce chondrogenic differentiation to produce cartilage tissue. Furthermore, the produced cartilage tissue does not contain cells other than chondrocytes, making it advantageous for use in regenerative medicine. The present invention was developed based on the discovery that producing cartilage tissue from such chondroprogenitor cells under specified culture conditions enables efficient cell proliferation and the creation of large cartilage tissue fragments from a small number of cells.

[0006] The present invention encompasses the following. [1] A substrate having cell adhesion inhibitory properties is coated with the following formula (I): [ka] [In the formula, U a1 and U a2 each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; R a1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; R a2 represents a linear or branched alkylene group having 1 to 5 carbon atoms], and a repeating unit derived from a monomer represented by the following formula (II): [ka] [In the formula, R b A method for producing cartilage tissue, comprising the steps of: providing a substrate for producing cell aggregates having a plurality of spots made of a copolymer containing repeating units derived from a monomer represented by the formula [wherein represents a hydrogen atom or a straight-chain or branched alkyl group having 1 to 5 carbon atoms]; seeding human chondroprogenitor cells derived from pluripotent stem cells and positive for PRRX1 protein onto the substrate; culturing the cells to produce cell aggregates; and culturing the aggregates to produce cartilage tissue.

[0007] [2] The production method according to the above [1], wherein the molar ratio of the repeating units derived from the monomer represented by formula (I) to the total of the repeating units derived from the monomer represented by formula (I) and the repeating units derived from the monomer represented by formula (II) is 99 mol % to 51 mol %.

[0008] [3] The copolymer further comprises a compound represented by the following formula (III): [ka] [In the formula, R c and R d each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; R e represents a linear or branched alkylene group having 1 to 5 carbon atoms, and n represents a number from 1 to 50.

[0009] [4] The substrate having the cell adhesion inhibitory ability is a copolymer (P) containing a repeating unit containing a group represented by the following formula (a) and a repeating unit containing a group represented by the following formula (b): [ka] [In the formula, U a11 , U a12 , U b11 , U b12 and U b13 each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; An - represents an anion selected from the group consisting of a halide ion, an inorganic acid ion, a hydroxide ion, and an isothiocyanate ion. The method according to any one of the above [1] to [3], wherein the coating film containing the compound is included on at least a part of the surface thereof.

[0010] [5] The method according to any one of [1] to [4] above, wherein the culturing in the step of producing the cartilage tissue mass is carried out in a medium containing agar.

[0011] [6] The method according to [5] above, wherein the weight-average molecular weight of the agar is 10,000 to 60,000, and the agar content is 0.005 (w / v)% or more and less than 2 (w / v)% of the total volume of the medium. [Effects of the Invention]

[0012] The production method of the present invention is advantageous in that it uses quality-controlled chondroprogenitor cells as a raw material and can produce cartilage tissue by inducing chondrocyte differentiation, and the produced cartilage tissue does not contain any cells other than chondrocytes, making it possible to safely use cartilage tissue in regenerative medicine. Furthermore, by producing cartilage tissue from chondroprogenitor cells under specified culture conditions, it is possible to efficiently grow cells and produce large cartilage tissue pieces from a small number of cells, which is also advantageous in terms of cost. [Brief explanation of the drawings]

[0013] [Figure 1] This shows an overall image (top left) and a magnified image (bottom left) of a cell aggregate formed on the cell aggregate production substrate obtained in Example 1, and an overall image (top right) and a magnified image (bottom right) of a cell aggregate visualized by expression of the red fluorescent protein (tdTomato). [Figure 2]1 is a stereomicroscopic photograph of the cartilage tissue mass obtained in Example 1. [Figure 3] 1 is an inverted microscope photograph (bright field) of the cartilage tissue mass obtained in Example 1. [Figure 4] 1 shows images of tissue sections of the cartilage tissue specimen obtained in Example 1, stained with hematoxylin (HE) (left), Alcian blue (center), or Safranin O (right). [Figure 5] In Evaluation Example 1, these are images of tissue pieces collected 4 weeks after transplantation of the cartilage tissue obtained in Example 1, stained with HE (left), Safranin O (center), or toluidine blue (right). DETAILED DESCRIPTION OF THE INVENTION

[0014] <Method of manufacturing cartilage tissue> The method for producing a cartilage tissue of the present invention comprises the steps of: (1) providing a substrate for producing cell aggregates, the substrate having a cell adhesion-inhibiting ability and including a plurality of spots made of a copolymer containing repeating units derived from the monomers represented by formulas (I) and (II); (2) seeding PRRX1 protein-positive human chondroprogenitor cells derived from pluripotent stem cells onto the substrate; (3) culturing the cells to form cell aggregates; and (4) culturing the aggregate to prepare a cartilage tissue mass; The present invention is characterized by comprising:

[0015] Process (1) In step (1), a substrate for producing a cell aggregate is provided. The substrate for producing a cell aggregate according to the present invention has a plurality of spots formed on a substrate having cell adhesion-inhibiting ability, the spots being made of a copolymer containing repeating units derived from monomers represented by formulas (I) and (II).

[0016] (copolymer) The copolymer has the following formula (I): [ka] [In the formula, U a1 and U a2 each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; R a1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; R a2 represents a linear or branched alkylene group having 1 to 5 carbon atoms], and a repeating unit derived from a monomer represented by the following formula (II): [ka] [In the formula, R b represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms].

[0017] Unless otherwise defined, in this specification, examples of a "linear or branched alkyl group having 1 to 5 carbon atoms" include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, an s-butyl group, a t-butyl group, an n-pentyl group, a 1-methylbutyl group, a 2-methylbutyl group, a 3-methylbutyl group, a 1,1-dimethylpropyl group, a 1,2-dimethylpropyl group, a 2,2-dimethylpropyl group, and a 1-ethylpropyl group.

[0018] R a1 and R b are preferably each independently selected from a hydrogen atom and a methyl group.

[0019] U a1 and U a2 are each independently preferably selected from a hydrogen atom, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, and an n-butyl group, more preferably a methyl group or an ethyl group, and most preferably a methyl group.

[0020] In this specification, unless otherwise defined, examples of a "linear or branched alkylene group having 1 to 5 carbon atoms" include a methylene group, an ethylene group, a propylene group, a trimethylene group, a tetramethylene group, a 1-methylpropylene group, a 2-methylpropylene group, a dimethylethylene group, an ethylethylene group, a pentamethylene group, a 1-methyl-tetramethylene group, a 2-methyl-tetramethylene group, a 1,1-dimethyl-trimethylene group, a 1,2-dimethyl-trimethylene group, a 2,2-dimethyl-trimethylene group, and a 1-ethyl-trimethylene group. a2 is preferably selected from an ethylene group and a propylene group.

[0021] Therefore, examples of the monomer represented by the formula (I) include 2-N,N-dimethylaminoethyl methacrylate and N,N-dimethylaminomethyl methacrylate, with 2-N,N-dimethylaminoethyl methacrylate being preferred. Examples of the monomer represented by the formula (II) include acrylic acid and methacrylic acid, with methacrylic acid being preferred.

[0022] The molar ratio of the repeating units derived from the monomer of formula (I) in the copolymer to the sum of the repeating units derived from the monomer of formula (I) and the repeating units derived from the monomer of formula (II) is preferably 99 mol% to 51 mol%, more preferably 98 mol% to 60 mol%, even more preferably 95 mol% to 70 mol%, and even more preferably 93 mol% to 70 mol%. If the molar ratio of the repeating units derived from the monomer of formula (II) is 50 mol% or more, the copolymer tends to become excessively anionic, resulting in reduced cell adhesion. Unless otherwise specified, the molar ratio of the repeating units derived from each monomer can be replaced with the ratio calculated from the amount (molar amount) of the monomer charged.

[0023] The copolymer may contain, in addition to the repeating units derived from the monomers represented by formula (I) / formula (II), structural units derived from a monomer having two or more carbon-carbon unsaturated bonds. The monomer having two or more carbon-carbon unsaturated bonds is specifically a monomer having two or more carbon-carbon double bonds, such as a polyfunctional acrylate compound, a polyfunctional acrylamide compound, a polyfunctional polyester, or an isoprene compound.

[0024] Preferred specific examples include monomers represented by the following formulas (III) to (V). [ka] [ka] [ka]

[0025] In the formula, R c and R d each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; R e represents a linear or branched alkylene group having 1 to 5 carbon atoms, and n represents a number from 1 to 50. Among these, the monomer represented by formula (III) is preferred.

[0026] R c and R d are preferably each independently selected from a hydrogen atom and a methyl group. R e is preferably selected from a methylene group, an ethylene group, and a propylene group, and more preferably an ethylene group.

[0027] Although n is a number from 1 to 50, n is preferably a number from 1 to 30, and more preferably a number from 1 to 10.

[0028] The molar ratio of repeating units derived from monomers having two or more carbon-carbon unsaturated bonds (typically, monomers represented by formulas (III) to (V)) in the copolymer is preferably 0 mol % to 5 mol %, more preferably 0 mol % to 3 mol %. If the molar ratio of repeating units derived from monomers having two or more carbon-carbon unsaturated bonds exceeds 5 mol %, excessive crosslinking may cause high molecular weight, resulting in gelation during production, making production difficult.

[0029] The copolymer may further contain, as an optional additional monomer component, a repeating unit derived from an ethylenically unsaturated monomer or a polysaccharide or a derivative thereof. Examples of the ethylenically unsaturated monomer include one or more ethylenically unsaturated monomers selected from the group consisting of (meth)acrylic acid esters, vinyl acetate, vinylpyrrolidone, ethylene, vinyl alcohol, and hydrophilic functional derivatives thereof. Examples of polysaccharides or derivatives thereof include cellulose-based polymers such as hydroxyalkyl cellulose (e.g., hydroxyethyl cellulose or hydroxypropyl cellulose), starch, dextran, and curdlan.

[0030] The hydrophilic functional derivative refers to an ethylenically unsaturated monomer having a hydrophilic functional group or structure. Examples of the hydrophilic functional group or structure include a betaine structure, an amide structure, an alkylene glycol residue, an amino group, and a sulfinyl group.

[0031] The betaine structure means a monovalent or divalent group of a compound having an amphoteric center of a quaternary ammonium type cation structure and an acidic anion structure, such as a phosphorylcholine group: [ka] An example of an ethylenically unsaturated monomer having such a structure is 2-methacryloyloxyethyl phosphorylcholine (MPC).

[0032] The amide structure has the following formula: [ka] [where R 16 , R 17 and R 18 are each independently a hydrogen atom or an organic group (for example, an optionally substituted linear or branched alkyl group having 1 to 5 carbon atoms, specifically, a methyl group, an isopropyl group, a hydroxymethyl group, a hydroxyethyl group, etc.). It means a group represented by the formula: Examples of ethylenically unsaturated monomers having such a structure include (meth)acrylamide, N-isopropylacrylamide, and N-(hydroxymethyl)(meth)acrylamide. Furthermore, monomers having such a structure are disclosed, for example, in JP-A-2010-169604.

[0033] The alkylene glycol residue refers to an alkyleneoxy group (-Alk-O-) remaining after one or both terminal hydroxyl groups of alkylene glycol (HO-Alk-OH; where Alk is an alkylene group having 1 to 10 carbon atoms) undergo a condensation reaction with another compound, and also includes poly(alkyleneoxy) groups in which alkyleneoxy units are repeated. Examples of ethylenically unsaturated monomers having such a structure include 2-hydroxyethyl (meth)acrylate and methoxypolyethylene glycol (meth)acrylate. Further, monomers having such a structure are disclosed, for example, in JP 2008-533489 A.

[0034] Amino groups have the formula: -NH2, -NHR 19 or -NR 20 R 21 [where R 19 , R 20 and R 21are each independently an organic group (for example, a linear or branched alkyl group having 1 to 5 carbon atoms). The amino group in the present invention includes quaternized or salified amino groups. Examples of ethylenically unsaturated monomers having such a structure include dimethylaminoethyl (meth)acrylate, 2-(t-butylamino)ethyl (meth)acrylate, and methacryloylcholine chloride.

[0035] The sulfinyl group has the formula: [ka] [where R 22 is an organic group (for example, an organic group having 1 to 10 carbon atoms, preferably an alkyl group having 1 to 10 carbon atoms having one or more hydroxy groups, etc.) The sulfinyl group may be introduced by the method disclosed in JP-A-2014-48278.

[0036] The copolymer of the present application can be produced by a method known per se (for example, the method described in JP-A-2014-162865 and WO 2020 / 040247).

[0037] The number average molecular weight (Mn) of the copolymer is 20,000 to 1,000,000, and more preferably 50,000 to 800,000. The ratio (Mw / Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) of the copolymer is 1.01 to 10.00, preferably 1.2 to 8.0, more preferably 1.4 to 6.0, even more preferably 1.5 to 5.0, and even more preferably 1.6 to 4.5. The number average molecular weight (Mn) and the number average molecular weight (Mn) can be determined, for example, by gel filtration chromatography.

[0038] By using the copolymer, cells can be attached and then detached to form cell aggregates (spheroids). Note that cell aggregates refer to structures formed as a result of cell aggregation, and are not limited to shapes such as spheres or rings.

[0039] (substrate) The substrate for producing cell aggregates used in the present invention can be produced by spot-coating the copolymer on the surface of the substrate and drying it. Here, the "surface" refers to the surface that comes into contact with the contents, such as cells or cell culture medium, and particularly, when the substrate is part of a cell culture vessel, it refers to the bottom surface of the surface that comes into contact with the contents.

[0040] The shape of the substrate surface may be flat or uneven, but a flat shape is preferred. The substrate may also be a so-called cell culture vessel or a part thereof. Examples of cell culture vessels include Petri dishes or dishes such as tissue culture dishes and multi-dishes commonly used for cell culture, flasks such as cell culture flasks and spinner flasks, bags such as plastic bags, Teflon (registered trademark) bags and culture bags, plates such as microplates, microwell plates, multi-plates and multi-well plates, chamber slides, tubes, trays, bottles such as roller bottles, and the like.

[0041] Examples of materials for the substrate include glass, metals, metal-containing compounds or metalloid-containing compounds, activated carbon, and resins. Examples of metals include typical metals (aluminum group elements: Al, Ga, In; iron group elements: Fe, Co, Ni; chromium group elements: Cr, Mo, W, U; manganese group elements: Mn, Re; and noble metals: Cu, Ag, Au). Examples of metal-containing compounds or metalloid-containing compounds include ceramics, which are sintered bodies whose basic component is a metal oxide and are hardened by heat treatment at high temperatures; semiconductors such as silicon; inorganic solid materials such as molded bodies of inorganic compounds such as metal oxides or metalloid oxides (silicon oxide, alumina, etc.); metal carbides or metalloid carbides; metal nitrides or metalloid nitrides (silicon nitride, etc.); and metal borides or metalloid borides; aluminum, nickel titanium, and stainless steel (SUS304, SUS316, SUS316L, etc.).

[0042] The resin may be a natural resin or a derivative thereof, or a synthetic resin. Preferred examples of natural resins or derivatives thereof include cellulose, cellulose triacetate (CTA), nitrocellulose (NC), and cellulose with immobilized dextran sulfate. Preferred examples of synthetic resins include polyacrylonitrile (PAN), polyimide (PI), polyester polymer alloy (PEPA), polystyrene (PS), polysulfone (PSF), polyethylene terephthalate (PET), polymethyl methacrylate (PMMA), polyvinyl alcohol (PVA), polyurethane (PU), ethylene vinyl alcohol (EVAL), polyethylene (PE), polyester, polypropylene (PP), polyvinylidene fluoride (PVDF), polyethersulfone (PES), polycarbonate (PC), cycloolefin polymer (COP), polyvinyl chloride (PVC), polytetrafluoroethylene (PTFE), ultra-high molecular weight polyethylene (UHPE), polydimethylsiloxane (PDMS), acrylonitrile-butadiene-styrene resin (ABS), and Teflon (registered trademark).

[0043] In the production of the substrate for producing cell aggregates used in the present invention, the copolymer is spot-coated on the surface of the substrate and dried without requiring high-temperature treatment, so resins with low heat resistance can also be used. The substrate material may be one type or a combination of two or more types.

[0044] (spot) The substrate for producing cell aggregates used in the present invention has a plurality of spots made of the copolymer. The ratio of the total area of ​​the spots to the surface area of ​​the substrate is not particularly limited, but is, for example, 30% or more, and the diameter of each spot is, for example, 50 to 5000 μm, with the spacing between spots being, for example, 30 to 1000 μm. The shape of the spots is not particularly limited, but may be, for example, approximately circular or rectangular, with approximately circular spots being preferred. The ratio of the total area of ​​the spots to the surface area of ​​the substrate, the diameter of each spot, and the spacing between spots can be selected appropriately from a predetermined range depending on the type of cells and substrate used, the desired size of the cell aggregates, etc., but the ratio of the total area of ​​the spots to the surface area of ​​the substrate is preferably 30% or more, 40% or more, 50% or more, and preferably 99% or less, the diameter of each spot is 50 to 5000 μm, preferably 300 to 3000 μm, and the spacing between spots is 30 to 1000 μm, preferably 100 to 500 μm.

[0045] By arranging independent micro-sized areas (spots) to which cells can adhere at high density, preferably in a regular pattern, on a substrate with cell adhesion inhibitory properties, multiple uniformly sized spheroids can be formed simultaneously on a single substrate (container). Compared to cell aggregates produced by non-adhesive culture on conventional low-adhesion plates, this method offers advantages such as the ability to adjust the size of the cell aggregates by specifying the adhesion area (i.e., the ability to produce cell aggregates of any size).

[0046] The spots made of the copolymer can be formed by applying the copolymer, preferably a primer containing the copolymer. The primer can be prepared by mixing the copolymer with a water-containing solution by a method known per se. Such a primer is useful for promoting cell aggregate formation.

[0047] The aqueous solution may be water, a salt-containing aqueous solution such as physiological saline or phosphate buffer solution, or a mixed solvent of water or a salt-containing aqueous solution with an alcohol. Examples of the alcohol include alcohols having 2 to 6 carbon atoms, such as ethanol, propanol, isopropanol, 1-butanol, 2-butanol, isobutanol, t-butanol, 1-pentanol, 2-pentanol, 3-pentanol, 1-heptanol, 2-heptanol, 2,2-dimethyl-1-propanol (neopentyl alcohol), 2-methyl-1-propanol, 2-methyl-1-butanol, 2-methyl-2-butanol (t-amyl alcohol), 3-methyl-1-butanol, 3-methyl-3-pentanol, cyclopentanol, 1-hexanol, and the like. Examples of suitable solvents include 2-methyl-1-pentanol, 2-methyl-2-pentanol, 2-methyl-3-pentanol, 3-methyl-1-pentanol, 3-methyl-2-pentanol, 3-methyl-3-pentanol, 4-methyl-1-pentanol, 4-methyl-2-pentanol, 4-methyl-3-pentanol, and cyclohexanol. These solvents may be used alone or in combination.

[0048] In addition to the copolymer and solvent, other substances may be added to the primer as needed, provided that they do not impair the performance of the resulting primer film, such as pH adjusters, crosslinkers, preservatives, surfactants, primers that improve adhesion to the container or substrate, antifungal agents, and sugars.

[0049] The primer can be applied by, for example, an inkjet method, a screen printing method, a slit coating method, a roll-to-roll method, or the like, but is preferably applied by a printing technique such as an inkjet method or screen printing.

[0050] Other application methods include, for example, immersing a substrate, optionally with non-spotted areas protected, in the primer, or adding the primer to a substrate (container), optionally with non-spotted areas protected, and leaving it to stand for a predetermined period of time. In the case of a substrate, or in one embodiment, a cell culture vessel, the primer is added to a container, optionally with non-spotted areas protected, and then left to stand for a predetermined period of time. The addition can be carried out, for example, by adding the primer in an amount 0.5 to 1 times the total volume of the vessel using a syringe or the like. The time and temperature for leaving the substrate to stand are appropriately selected depending on the material of the vessel or substrate and the type of cell culture primer, but are typically carried out at 10 to 80°C for 1 minute to 24 hours, preferably 5 minutes to 3 hours. This allows the production of a substrate for cell aggregate production.

[0051] Furthermore, the spots on the surface of the substrate obtained by this method can be used as a substrate for producing cell aggregates either as is without a drying step, or after washing with water or the medium of the sample to be subjected to cell culture (e.g., water, buffer solution, culture medium, etc.).

[0052] That is, after the formation of spots on the surface of the substrate, the substrate can be used as a substrate for producing cell aggregates within 48 hours, preferably within 24 hours, more preferably within 12 hours, even more preferably within 6 hours, even more preferably within 3 hours, and even more preferably within 1 hour, either as is without a drying step, or after washing with water or the medium of the sample to be subjected to cell culture (e.g., water, buffer solution, culture medium, etc., particularly preferably culture medium (e.g., DMEM medium (Dulbecco's modified Eagle's medium))).

[0053] The substrate for producing cell aggregates may be subjected to a drying process. The drying process is carried out in the atmosphere or under vacuum, preferably at a temperature in the range of −200° C. to 200° C. The drying process removes the solvent in the primer, thereby completely adhering it to the base.

[0054] The spots can be formed by drying at room temperature (10°C to 35°C, preferably 20°C to 30°C, e.g., 25°C), but to form the spots more quickly, drying may be performed at, for example, 40°C to 50°C. If the drying temperature is lower than -200°C, an uncommon refrigerant must be used, which is insufficient for versatility, and drying takes a long time due to solvent sublimation, resulting in poor efficiency. If the drying temperature is higher than 200°C, thermal decomposition of the copolymer occurs. A more preferred drying temperature is 10°C to 180°C, and even more preferred is 20°C to 150°C.

[0055] The substrate for producing cell aggregates used in the present invention is produced through the above-described simple steps. Furthermore, in order to remove impurities, unreacted monomers, etc. remaining on the spot (coated film), a step of washing with at least one solvent selected from water and an aqueous solution containing an electrolyte may be carried out. Washing is preferably performed using running water or ultrasonic cleaning. The aqueous solution containing water and an electrolyte may be heated, for example, to a temperature in the range of 40°C to 95°C. Preferred aqueous solutions containing electrolytes include PBS, saline (containing only sodium chloride), Dulbecco's phosphate-buffered saline, Tris-buffered saline, HEPES-buffered saline, and Veronal-buffered saline, with PBS being particularly preferred. After adhesion, the coating film remains firmly adhered to the substrate without elution even when washed with water, PBS, alcohol, etc.

[0056] The maximum and minimum film thicknesses of the spots (coated films) are in the range of 1 to 1000 nm, preferably 5 to 500 nm.

[0057] The substrate for producing cell aggregates used in the present invention is produced using a substrate having cell adhesion-inhibiting properties. Such substrates may include commercially available cell culture dishes that have been treated to reduce cell adhesion, cell culture vessels that have cell adhesion-inhibiting properties, and the like. For example, the cell culture vessels described in JP 2008-61609 A can be used, but are not limited to these. Alternatively, the substrate may be subjected to a cell adhesion-inhibiting treatment before the formation of the spots (coating film). Substrates having cell adhesion-inhibiting properties can be produced, for example, by applying a known coating film-forming composition having cell adhesion-inhibiting properties. Examples of coating film-forming compositions having cell adhesion-inhibiting properties include copolymers (P) containing a repeating unit containing an organic group represented by the following formula (a) and a repeating unit containing an organic group represented by the following formula (b): [ka] [In the formula, U a11 , U a12 , U b11 , U b12 and U b13 each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; An - represents an anion selected from the group consisting of a halide ion, an inorganic acid ion, a hydroxide ion, and an isothiocyanate ion. and a solvent, and applying the composition for forming a coating film to the surface of a container or a substrate, and drying the composition. The coating film may be present on at least a portion of the surface of the substrate, but is preferably applied over the entire surface on which cell aggregates are produced (i.e., the surface on which the spots of the present application are present) or over the entire surface of the substrate. The straight-chain or branched alkyl group having 1 to 5 carbon atoms is the same as that described above.

[0058] As the composition for forming a coating film, for example, the composition for forming a coating film described in International Publication No. 2014 / 196650 can be used.

[0059] The method for applying the coating film-forming composition is not particularly limited, and a typical application method such as spin coating, dip coating, or solvent casting can be used.

[0060] The drying step of the coating film is carried out in the atmosphere or under vacuum at a temperature ranging from −200° C. to 180° C. The drying step removes the solvent from the composition for forming a coating film, and also forms ionic bonds between the copolymers of formula (a) and formula (b), thereby completely fixing the composition to the substrate.

[0061] The coating film can be formed by drying at room temperature (10°C to 35°C, e.g., 25°C), but drying at 40°C to 50°C may be used to form the coating film more quickly. A drying process at extremely low to low temperatures (around -200°C to -30°C) using the freeze-drying method may also be used. Freeze-drying is also called vacuum freeze-drying, and is a method in which the material to be dried is cooled with a refrigerant and the solvent is removed by sublimation in a vacuum. Common refrigerants used in freeze-drying include a mixture of dry ice and methanol (-78°C) and liquid nitrogen (-196°C). If the drying temperature is below -200°C, an uncommon refrigerant must be used, resulting in a lack of versatility and inefficiency due to the long drying time required due to solvent sublimation. If the drying temperature is above 200°C, the ionic bonding reaction on the coating film surface will proceed too much, causing the surface to lose its hydrophilicity and preventing the biomaterial adhesion inhibitory effect from being exerted. A more preferred drying temperature is 10°C to 180°C, and even more preferred is 25°C to 150°C.

[0062] After drying, the coating film is preferably washed with running water or ultrasonically with one or more solvents selected from water and an aqueous solution containing an electrolyte to remove impurities, unreacted monomers, etc. remaining on the coating film and to adjust the ion balance of the copolymer in the film. The aqueous solution containing water and an electrolyte may be heated, for example, to a temperature between 40°C and 95°C. Preferred aqueous solutions containing electrolytes include PBS, saline (containing only sodium chloride), Dulbecco's phosphate-buffered saline, Tris-buffered saline, HEPES-buffered saline, and Veronal-buffered saline, with PBS being particularly preferred. After adhesion, the coating film remains firmly attached to the substrate without elution even when washed with water, PBS, alcohol, etc. Even if biological materials adhere to the formed coating film, they can be easily removed by subsequent washing with water, etc., and the substrate surface on which the coating film is formed has the ability to inhibit adhesion of biological materials.

[0063] The thickness of the coating film is preferably 5 to 1000 nm, and more preferably 5 to 500 nm.

[0064] Having the ability to inhibit cell adhesion means that the relative absorbance (WST OD450nm) (%) ((absorbance (WST OD450nm) of the example) / (absorbance (WST OD450nm) of the comparative example)) when compared to a sample without a coating film or without low cell adhesion treatment, measured using a fluorescence microscope using the method described in the examples of WO2016 / 093293, for example, is 50% or less, preferably 30% or less, and more preferably 20% or less.

[0065] Process (2) In step (2), human chondroprogenitor cells that are PRRX1 protein-positive and derived from pluripotent stem cells are seeded onto the substrate for producing a cell aggregate.

[0066] "Pluripotent stem cells" refer to cells that have both the ability to self-renew and the ability to differentiate into cells of multiple lineages (multipotency), and "progenitor cells" refer to cells that are in the process of differentiating from stem cells into functional cells, which are their final differentiation destination. Therefore, human chondroprogenitor cells derived from pluripotent stem cells refer to cells that have been induced to differentiate from pluripotent stem cells as source cells and are in the process of differentiating into chondrocytes, which are their final differentiation destination. Examples of pluripotent stem cells include multipotent cells (cells that have the ability to differentiate into all somatic cells and germline cells), such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

[0067] Furthermore, in the present invention, the "human chondroprogenitor cells" are positive for the PRRX1 protein. The PRRX1 (Paired related homeobox 1) protein is a transcription factor with a homeodomain, and is known to be specifically expressed in limb buds derived from the lateral plate mesoderm and in head mesoderm derived from the paraxial mesoderm during development.

[0068] The cDNA nucleotide sequence of the human (Homo sapiens) PRRX1 gene and the amino acid sequence of the PRRX1 protein have been registered in GenBank, provided by the National Center for Biotechnology Information (NCBI), under the following accession numbers. Note that if multiple revisions are registered, the most recent revision is understood to be the one being referred to. - Human PRRX1 gene: NM_006902 (NM_006902.5), NM_022716 (NM_022716.4) - Human PRRX1 protein: NP_008833 (NP_008833.1), NP_073207 (NP_073207.1)

[0069] Whether a cell is positive for the PRRX1 protein can be detected by known techniques, such as detection using a reporter gene whose expression is controlled by the transcription promoter sequence of the PRRX1 gene, or detection by immunostaining using an antibody specific to the PRRX1 protein.

[0070] PRRX1 protein-positive chondroprogenitor cells can be produced, for example, by a method comprising the following steps: - inducing differentiation of pluripotent stem cells into lateral plate mesoderm cells; - culturing the cells induced to differentiate by the above step under an environment that activates Wnt signaling to prepare limb bud mesenchymal cells; - A step of culturing the limb bud mesenchymal cells prepared in the above step in an environment that activates Wnt signaling to prepare chondrocyte precursor cells.

[0071] In the above-mentioned method, pluripotent stem cells used as starting cells can be, for example, embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), etc. ES cells and iPS cells can be newly prepared or already established.

[0072] In the above-described method, first, pluripotent stem cells are induced to differentiate into lateral plate mesoderm cells. Known methods can be used to induce differentiation of pluripotent stem cells into lateral plate mesoderm cells. For example, a method similar to the method described in the literature (Loh et al., 2016, Cell, 451-467) can be employed. Specifically, pluripotent stem cells are first induced to differentiate into a primitive streak (mid-primitive streak), and then the primitive streak is induced to differentiate into lateral plate mesoderm cells.

[0073] The induction of differentiation of lateral plate mesoderm cells can be confirmed, for example, by detecting the expression of HAND1 protein, a specific marker for lateral plate mesoderm cells.

[0074] The differentiation-induced lateral plate mesoderm cells are then cultured in an environment that activates Wnt signaling, and are induced to differentiate into PRRX1 protein-positive, lateral plate mesoderm-derived PRRX1-positive cells. To reduce the influence of the previous culture environment, it is preferable to wash the cells appropriately with PBS buffer or the like before culturing them in an environment that activates Wnt signaling.

[0075] The differentiation induction of lateral plate mesoderm cells into limb bud mesenchymal cells is also preferably carried out in the absence of an FGF signal activator such as FGF2, more preferably in an environment that activates Wnt signaling and in the presence of one, two, or three inhibitors selected from the group consisting of a TGFβ signal inhibitor, a BMP signal inhibitor, and a hedgehog signal inhibitor, and even more preferably in the presence of a TGFβ signal inhibitor, a BMP signal inhibitor, a TGFβ signal inhibitor, and a hedgehog signal inhibitor.

[0076] Culturing under an environment that activates Wnt signaling can be achieved, for example, by culturing in the presence of an effective amount of a Wnt signaling activator. Wnt signaling activators enhance signal transduction mediated by Wnt (particularly the canonical Wnt pathway). Examples of Wnt signaling activators include GSK3β inhibitors and Wnt family proteins. Examples of GSK3β inhibitors include CHIR99021 (6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile), XAV939 (3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one), and LiC1. When CHIR99021 is used as the Wnt signal activator, the amount added can be, for example, about 0.1 to 20 μM, preferably 1 to 10 μM.

[0077] BMP signal inhibitors suppress (inhibit) signal transduction mediated by BMP. Examples of BMP signal inhibitors include LDN193189 (4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) or a salt thereof (e.g., hydrochloride), DMH-1, etc., and the amount of the inhibitor added can be, for example, about 0.1 to 10 μM, preferably 0.2 to 5 μM. TGFβ signal inhibitors suppress (inhibit) signal transduction mediated by TGFβ. Examples of TGFβ signal activators include A-83-01 (3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide) and SB431542, and the amount of these activators added can be, for example, about 0.1 to 10 μM, preferably 0.2 to 5 μM. Hedgehog signal inhibitors suppress (inhibit) signal transduction mediated by hedgehog. Examples of hedgehog signal activators include vismordegib, cyclopamine, and sonidegib, and the amount of each agent added can be, for example, about 10 nM to 1 μM, preferably about 50 nM to 500 nM.

[0078] The culturing method may be, but is not limited to, culturing at about 37°C and with a carbon dioxide concentration of about 5%. Culturing under the above conditions can be performed, for example, using a known CO incubator while controlling the temperature and CO concentration.

[0079] The culture can be performed by two-dimensional cell culture (plate culture). Two-dimensional cell culture can be performed by coating the culture equipment as needed to promote cell adhesion.

[0080] The period of culturing under an environment that activates Wnt signaling is not particularly limited, but can be, for example, about 6 hours to 4 days, preferably about 1 to 3 days, and more preferably about 2 days (about 48 hours). The medium can be changed as necessary. Culture conditions are preferably in accordance with conventional methods.

[0081] During culture, passage can be performed as necessary. When passage is performed, the cells are collected before or immediately after reaching a confluent state and seeded in a new medium. The medium can also be replaced as appropriate.

[0082] It is preferable to use a serum-free medium such as IMDM medium, F12 medium, or a mixture thereof. Differentiation induction and maintenance culture can be performed without containing animal-derived components. The serum-free medium can also be supplemented with various medium additives, such as antibiotics such as streptomycin and penicillin, non-essential amino acids (NEAA), ROCK inhibitors (e.g., Y-27632 ((R)-(+)-trans-N-(4-Pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide·2HCl)), hormones such as insulin, proteins such as transferrin and albumin, lipids, polyvinyl alcohol, and monothioglycerol.

[0083] The prepared limb bud mesenchymal stem cells are then cultured under an environment that activates Wnt signaling, and induced to differentiate into PRRX1 protein-positive chondroprogenitor cells. The "environment that activates Wnt signaling" has the same meaning as above. Furthermore, it is preferable that the differentiation of limb bud mesenchymal cells into chondroprogenitor cells be performed in the presence of an FGF signal activator such as FGF2.

[0084] In this way, PRRX1 protein-positive chondroprogenitor cells are produced. Specific embodiments are as described in the Examples below. Reference can also be made to the description in International Publication No. 2021 / 054449. Furthermore, the chondroprogenitor cells obtained in this manner can be expanded in the same lot and stored under certain quality control conditions.

[0085] The seeding of human chondroprogenitor cells onto the substrate for producing cell aggregates is carried out by a method known per se, such as suspending the cells in a culture medium, for example, the medium used for culturing in the subsequent step (3), to form a cell suspension, and then adding this to the substrate for producing cell aggregates.

[0086] Process (3) In step (3), PRRX1 protein-positive human chondroprogenitor cells derived from pluripotent stem cells are cultured to produce cell aggregates. The culturing method is not particularly limited as long as it is a method capable of producing a cell aggregate from the human chondroprogenitor cells, and is appropriately selected depending on the properties of the human chondroprogenitor cells, etc.

[0087] For example, PRRX1 protein-positive human chondroprogenitor cells derived from pluripotent stem cells are preferably cultured in an environment that activates Wnt signaling and / or an environment that suppresses TGFβ signaling.

[0088] Culturing under an environment that activates Wnt signaling can be achieved, for example, by culturing in the presence of an effective amount of a Wnt signaling activator. Wnt signaling activators enhance signal transduction mediated by Wnt (particularly the canonical Wnt pathway). Examples of Wnt signaling activators include GSK3β inhibitors and Wnt family proteins. Examples of GSK3β inhibitors include CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile), XAV939 (3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one), and LiC1. When CHIR99021 is used as the Wnt signal activator, the amount added can be, for example, about 0.1 to 20 μM, preferably 1 to 10 μM.

[0089] Culturing under an environment that suppresses TGFβ signaling can be achieved, for example, by culturing in the presence of an effective amount of a TGFβ signaling inhibitor. A TGFβ signaling inhibitor suppresses (inhibits) signal transduction mediated by TGFβ. Examples of TGFβ signaling inhibitors include A-83-01 (3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazol-1-carbothioamide) and SB431542 (4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide). When A-83-01 is used as the TGFβ signaling inhibitor, the amount added can be, for example, about 0.1 to 10 μM, preferably 0.2 to 5 μM.

[0090] The culturing method may be, but is not limited to, culturing at about 37°C and with a carbon dioxide concentration of about 5%. Culturing under the above conditions can be performed, for example, using a known CO incubator while controlling the temperature and CO concentration.

[0091] The culturing period is not particularly limited, but can be, for example, about 6 hours to 4 days, preferably about 1 to 3 days, and more preferably about 2 days (about 48 hours). The medium can be changed as necessary. The culturing conditions are preferably in accordance with conventional methods.

[0092] It is preferable to use a serum-free medium such as IMDM medium, F12 medium, or a mixture thereof. Differentiation induction and maintenance culture are possible without containing animal-derived components. Furthermore, various medium additives can be added to the serum-free medium, such as antibiotics such as streptomycin and penicillin, non-essential amino acids (NEAA), ROCK inhibitors (e.g., Y-27632), cell growth factors such as EGF and FGF, hormones such as insulin, proteins such as transferrin and albumin, lipids, polyvinyl alcohol, and monothioglycerol.

[0093] In this manner, a cell aggregate is produced from human chondroprogenitor cells. Specific embodiments are as described in the Examples below.

[0094] By using the cell aggregate production substrate provided in step (1) with multiple spots made of a specific copolymer, it is possible to form cell aggregates by adhering cells to the spots and then detaching them. Note that a cell aggregate refers to a structure formed as a result of cell aggregation, and its shape is not limited to a spherical or ring shape. Compared to cell aggregates produced by non-adherent culture on conventional low-adhesion plates, this method has advantages such as the ability to adjust the size of the cell aggregate by specifying the adhesion area (cell aggregates of any size can be produced).

[0095] Process (4) In step (4), the cell aggregate obtained in the previous step is cultured to prepare a cartilage tissue. The culturing method is not particularly limited as long as it is a method that can produce a cartilage tissue from the cell aggregate, and is appropriately selected depending on the properties of the cell aggregate obtained from the human chondroprogenitor cells.

[0096] For example, it is preferable to culture a cell aggregate obtained from PRRX1 protein-positive human chondroprogenitor cells derived from pluripotent stem cells using a method including a step of culturing the cells in an environment that activates Wnt signaling.

[0097] Culturing under an environment that activates Wnt signaling can be achieved, for example, by culturing in the presence of an effective amount of a Wnt signaling activator. Wnt signaling activators enhance signal transduction mediated by Wnt (particularly the canonical Wnt pathway). Examples of Wnt signaling activators include GSK3β inhibitors and Wnt family proteins. Examples of GSK3β inhibitors include CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile), XAV939 (3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one), and LiC1. When CHIR99021 is used as the Wnt signal activator, the amount added can be, for example, about 0.1 to 20 μM, preferably 1 to 10 μM.

[0098] It is also preferable to culture in multiple stages. (i) culturing in the presence of a Wnt signal activator and an FGF signal activator; (ii) culturing in the presence of an FGF signal activator (and preferably in the absence of a Wnt signal activator); (iii) preferably culturing the cells in the absence of a Wnt signal activator and an FGF signal activator; It is preferable to carry out the above three steps.

[0099] Culturing under an environment that activates FGF signaling can be carried out, for example, by culturing in the presence of an effective amount of an FGF signal activator. FGF signal activators enhance fibroblast growth factor (FGF) signaling. Examples of FGF signal activators include FGF1 / aFGF and FGF2 / bFGF. When FGF2 is used as the FGF signal activator, the amount added can be, for example, about 0.1 to 100 ng / mL, preferably 1 to 50 ng / mL.

[0100] When culturing in the three stages, steps (i) and (ii) can be performed by two-dimensional cell culture (plate culture) or three-dimensional culture. Two-dimensional cell culture can be performed by coating the culture equipment as needed to promote cell adhesion. Step (iii) is preferably performed by three-dimensional culture. Between each stage of culture, it is preferable to appropriately wash the cells with PBS buffer or the like before culturing in order to reduce the influence of the previous culture environment.

[0101] The culture can be carried out in a suitable container for storing cells and culture medium. Suitable culture methods include, but are not limited to, culturing at approximately 37°C and with a carbon dioxide concentration of approximately 5%. Culture under the above conditions can be carried out, for example, using a known CO2 incubator while controlling the temperature and CO2 concentration.

[0102] The period of culturing under an environment that activates Wnt signaling is not particularly limited, as long as it does not impair the effects of the present invention. For example, it can be about 2 hours to 12 days, or about 4 to 8 days. Furthermore, when culturing is performed in multiple stages, for example, when culturing in the three stages described above, the periods for step (i) and step (ii) can be about 2 hours to 12 days, or about 4 to 8 days, respectively, and the period for step (iii) can be about 2 hours to 60 days, or about 8 to 54 days. If necessary, the medium can be changed during the culturing period. Culture conditions are preferably in accordance with conventional methods.

[0103] The culture can be passaged as necessary. When passaged, the cells are harvested before or immediately after reaching a confluent state and seeded in a new medium.

[0104] The medium used in the culture in step (4) is not particularly limited. Serum-free media such as IMDM medium, F12 medium, or a mixture thereof can be used. Furthermore, known cartilage induction media supplemented with L-ascorbic acid, ITS (insulin-transferrin-sodium selenite medium supplement), GDF5, and / or BMP4 can also be used. If necessary, various known medium additives can also be added, such as antibiotics such as streptomycin and penicillin, non-essential amino acids (NEAA), ROCK inhibitors (e.g., Y-27632), cell growth factors such as EGF and TGFβ, hormones such as insulin, proteins such as transferrin and albumin, lipids, polyvinyl alcohol, and monothioglycerol.

[0105] Furthermore, the medium used in the culture in step (4) preferably contains agar or an agar-containing medium composition.

[0106] Agar is composed of agarose and agaropectin, which is agarose partially sulfated or substituted with methoxy, pyruvic acid, or carboxyl groups, but there is no limitation on the ratio of these components, and agar may be composed solely of agarose. Also included in the term "agar" in the present invention are low-melting-point agarose obtained by hydroxyethylating agarose, low-melting-point agar prepared by selecting raw seaweed or by hydroxyethylating it, and fast-dissolving agar that is highly soluble in hot water.

[0107] In the present invention, industrially produced agar in powder, flake, or solid form is preferably used because of its high purity and uniform quality. Furthermore, agar having various properties and physical characteristics commonly used in the fields of pharmaceuticals, food, etc. can be used, including low-molecular-weight agar with a weight-average molecular weight of 10,000 to 60,000, low-strength agar with a weight-average molecular weight of more than 60,000 but not more than 100,000 and low gel strength, and high-molecular-weight agar with a weight-average molecular weight of approximately 290,000. Commercially available agars can be used, such as "Ultra Agar Ina," "Ultra Agar AX-30," "Ultra Agar AX-100," "S-6," and "S-7," all of which are sold by Ina Food Industry Co., Ltd.

[0108] In the present invention, it is preferable to use agar having a weight-average molecular weight of 10,000 to 60,000, which is lower than general agar (hereinafter, sometimes referred to as "low molecular weight agar" in this specification). As described above, the weight-average molecular weight of low molecular weight agar is 10,000 to 60,000, more preferably 20,000 to 60,000, even more preferably 30,000 to 60,000, even more preferably 40,000 to 60,000, even more preferably 43,000 to 60,000, and particularly preferably 43,000 to 50,000. When agar with a weight-average molecular weight of less than 10,000 is used, it may be difficult to achieve the effect of dispersing cells. On the other hand, when agar with a weight-average molecular weight exceeding 60,000 is used, cells or tissues may not be dispersed uniformly in the medium, and a sufficient growth-promoting effect may not be achieved.

[0109] Furthermore, the low molecular weight agar used in the present invention preferably has a narrow molecular weight distribution, and the molecular weight distribution (Mw / Mn), obtained by dividing the weight average molecular weight (Mw) of the agar by the number average molecular weight (Mn), is preferably 1.1 to 8.0, more preferably 1.5 to 7.0, even more preferably 2.0 to 6.0, even more preferably 2.5 to 5.5, and particularly preferably 3.5 to 5.0.

[0110] The weight average molecular weight and number average molecular weight of the agar can be measured by gel permeation chromatography using high performance liquid chromatography (HPLC).

[0111] The low molecular weight agar can be produced by known methods, such as by acid treatment of ordinary agar to reduce its molecular weight, or by acid treatment during the extraction process from seaweed such as Agar-agar, Gracilaria or Obakusa, or by acid treatment of agar that has been subjected to either the extraction process or the filtration process. However, commercially available products as low molecular weight agar, such as the above-mentioned "Ultra Agar Ina" (manufactured by Ina Food Industry Co., Ltd.), can also be used.

[0112] The agar can be added as a medium additive to the medium used in step (4) as is, or a medium composition containing the agar can be diluted with the medium used in step (4) to perform the culture. Examples of such agar-containing medium compositions include "SphereMAX™" (manufactured by Nissan Chemical Industries, Ltd.). Further specific embodiments of agar and agar-containing medium compositions are described in WO 2016 / 167373.

[0113] The agar content is preferably 0.005 (w / v)% or more and less than 2 (w / v)%, more preferably 0.03 (w / v)% or more and less than 2 (w / v)%, even more preferably 0.03 (w / v)% to 1 (w / v)%, and even more preferably 0.03 (w / v)% to 0.1 (w / v)%, based on the total volume of the medium used in step (4). When the agar content in the medium is 0.005 (w / v)% or more, cells grow without forming excessively large cell aggregates, and a cell proliferation-promoting effect is observed. Furthermore, when the agar content in the medium is 0.03 (w / v)% or more, a uniform dispersion of cells or tissues is obtained, which is more preferable. On the other hand, when the agar content in the medium composition is 2 (w / v)% or more, the medium may gel at room temperature, making it difficult to handle.

[0114] A cartilage tissue is produced in this manner. The fact that a cartilage tissue has been obtained can be confirmed by, for example, positive staining with safranin O staining, alcian blue staining, safranin O staining, or toluidine blue staining.

[0115] <Use of cartilage tissue> The present invention also relates to a method for treating articular cartilage damage in humans, which comprises transplanting a cartilage tissue obtained by the production method of the present invention into the site of articular cartilage damage or defect. Specific and preferred aspects of the method for producing a cartilage tissue are as described above. Transplantation can be carried out by placing one or more cartilage tissues obtained by the production method of the present invention into the site of articular cartilage damage or defect. [Example]

[0116] [Preparation Example 1] (Preparation of substrate for cell aggregate production) An aqueous solution of a copolymer of 2-(N,N-dimethylamino)ethyl methacrylate and methacrylic acid (with a molar ratio of 2-(N,N-dimethylaminoethyl) methacrylate to all monomers of 90%) was dropped in a 1.5cm square area in the center of the culture surface of a culture dish (diameter: 35mm) (Sumitomo Bakelite Co., Ltd., MS9035X) with cell adhesion inhibitory properties in a grid pattern at intervals of 300μm from top to bottom, left to right, and right to left using a droplet ejection device (MICROJET Corporation, BioSpot BT600).The droplets were then dried at room temperature for 15 minutes to solidify, preparing a substrate for producing cell aggregates with 350 independent circular spot areas with diameters of 100 to 1000μm to which cells could adhere.

[0117] [Preparation Example 2] (Preparation of PRRX1 protein-positive human chondroprogenitor cells) Human iPS cells (3 × 10 4 414C2 cells (provided by the Center for iPS Cell Research and Application, Kyoto University) were suspended in 1 mL of StemFit® (Ajinomoto Healthy Supply Co., Inc.) containing 10 μM CultureSure® Y-27632 (Fujifilm Wako Pure Chemical Industries, Ltd.) and 4 μL of iMatrix-511 (Nippi Corporation) and added to a 35 mm culture dish. The following day, the medium was replaced with fresh StemFit® without Y-27632. After two days of culture, the cells were washed with PBS and sequentially induced to differentiate into the mid-primitive streak, lateral plate mesoderm (LPM), and limb bud mesenchymal cells (LBM) by replacing the medium with the following compositions at each stage.

[0118] Primitive streak differentiation induction medium composition: Serum-free medium: 50% IMDM medium (Gibco) + 50% F12 medium (Gibco) + 1 mg / mL polyvinyl alcohol (Sigma-Aldrich) + 1% (v / v) lipid concentrate (Gibco) + 450 μM monothioglycerol (Sigma-Aldrich) + 0.7 μg / mL insulin (Sigma-Aldrich) + 15 μg / mL transferrin (Sigma-Aldrich) + 1% (v / v) penicillin / streptomycin (Gibco) (hereafter referred to as "CDM2 basal medium"). 30ng / mL activin A 40ng / mL BMP4 6 μM CHIR99021 100nM PIK90 (Funakoshi Co., Ltd.) 10 μM Y-27632

[0119] Lateral plate mesoderm (LPM) differentiation induction medium composition: CDM2 basal medium 1μM A-83-01 30ng / mL BMP4 1 μM C59 10 μM Y-27632

[0120] Limb bud mesenchymal cell (LBM) differentiation induction medium composition: CDM2 basal medium 1μM A-83-01 0.5 μM LDN-193189 3 μM CHIR99021 150nM vismodegib 10 μM Y-27632

[0121] The resulting LBM cells were then detached using Accutase (Thermo Fisher Scientific) and cultured at a concentration of 2 × 10 5The cells were suspended in the following human chondroprogenitor cell differentiation induction medium containing 16 μL of iMatrix-511 (Nippi Corporation) and added to a 60 mm culture dish. The medium was replaced with fresh human chondroprogenitor cell differentiation induction medium every two days to induce differentiation into human chondroprogenitor cells. The cells were passaged in the same manner before reaching subconfluence.

[0122] Human chondroprogenitor cell differentiation induction medium composition: CDM2 basal medium 1μM A-83-01 3 μM CHIR99021 20ng / mL FGF2 20ng / mL EGF 10 μM Y-27632

[0123] [Example 1] (Creation of cell aggregates) 1 × 10 cells obtained in Preparation Example 2 suspended in 1 mL of medium (CDM2 basal medium + 3 μM CHIR99021 + 1 μM A-83-01 + 20 ng / mL EGF + 20 ng / mL FGF) were added to the culture dish obtained in Preparation Example 1. 6 Human chondroprogenitor cells (hereinafter also referred to as "ExpLBM cells") were seeded and cultured at 37°C. The medium was changed after 4 hours. Two days after the medium change, the formation of cell aggregates was confirmed. The results are shown in Figure 1.

[0124] (Creation of cartilage tissue) The resulting cell aggregates were detached and transferred to an ultra-low attachment plate (6 well) (Corning #3471). The transferred cell aggregates were treated with Medium 1 for 6 days (day 0 to day 6: medium composition is described below), switched to Medium 2 on day 6 and treated for 6 days (day 6 to day 12: medium composition is described below), and then switched to Medium 3 and cultured for 42 days (day 12 to day 54: medium composition is described below) to obtain cartilage tissue. The results are shown in Figures 2 and 3. Figure 2 is a stereomicroscope photograph, and Figure 3 is a photograph taken in bright field using an inverted microscope.

[0125] Medium composition Medium 1: CDM2 basal medium + 3 μM CHIR99021 + 10 ng / mL FGF2 + 50 μg / mL ascorbic acid + 1×ITS + 4% low molecular weight agar-containing medium composition Medium 2: CDM2 basal medium + 10 ng / mL FGF2 + 50 μg / mL ascorbic acid + 30 ng / mL BMP4 + 10 ng / mL TGFβ1 + 10 ng / mL GDF5 + 1×ITS + 0.04% low molecular weight agar Medium 3: CDM2 basal medium + 50 μg / mL ascorbic acid + 30 ng / mL BMP4 + 10 ng / mL TGFβ1 + 10 ng / mL GDF5 + 1×ITS + 0.04% low molecular weight agar The low molecular weight agar-containing medium composition is a low molecular weight agar-containing medium composition prepared according to Test Example 10 of WO 2016 / 167373.

[0126] (Observation of cartilage tissue) The formed cartilage tissue was fixed with 4% PFA, tissue sections were prepared, and stained with hematoxylin (HE), alcian blue, and safranin O. The results are shown in Figure 4. The staining conditions were as follows: ·HE staining conditions After deparaffinization, the specimens were stained with eosin for 1 minute, and then treated with hematoxylin for 20 minutes to stain the nuclei. Alcian blue staining conditions After deparaffinization, the specimens were treated with 1% Alcian blue / 3% acetic acid for 20 minutes, washed with 3% acetic acid, and then treated with hematoxylin for 20 minutes for nuclear staining. Safranin O staining conditions After deparaffinization, the sections were stained with Weigert's iron hematoxylin solution for 10 minutes, followed by staining with fast green solution for 5 minutes, washing with 1% acetic acid, and then staining with 0.1% Safranin O solution for 5 minutes.

[0127] [Evaluation example 1] A biopsy trephine was used to create holes (1.5 mm in diameter, approximately 1 mm deep) in the knee articular cartilage of a SCID rat (supplied by the National BioResource Project - Rat, Tokyo University, Tokyo, Japan), and three cartilage tissue specimens prepared in Example 1 were inserted and transplanted. Four weeks after transplantation, tissue specimens were collected and subjected to various tissue stainings (HE staining, Safranin O staining, and toluidine blue staining). The results are shown in Figure 5. As shown in Figure 5, engraftment of the transplanted tissue at the defect site was observed, indicating that hyaline cartilage had formed at the same site. [Industrial Applicability]

[0128] The production method of the present invention is advantageous in that it uses quality-controlled chondroprogenitor cells as raw materials and can produce cartilage tissue by differentiation induction treatment, and the produced cartilage tissue does not contain cells other than chondrocytes, allowing for the safe use of cartilage tissue in regenerative medicine. Furthermore, by producing cartilage tissue from chondroprogenitor cells under specified culture conditions, it is possible to produce large cartilage tissue fragments from a small number of cells as well as efficiently proliferate the cells, which is also advantageous in terms of cost.

Claims

1. On a substrate having cell adhesion-inhibiting properties, a compound represented by the following formula (I): 【Chemical 1】 [In the formula, U ａ１ and U ａ２ represents a methyl group, and R a１ represents a methyl group, and R a２ represents an ethylene group], and a repeating unit derived from a monomer represented by the following formula (II): 【Chemistry 2】 [In the formula, R ｂ a step of seeding PRRX1 protein-positive human chondroprogenitor cells derived from pluripotent stem cells onto the substrate; a step of culturing the cells to produce a cell aggregate; and a step of culturing the aggregate to produce a cartilage tissue.

2. The production method according to claim 1, wherein the molar ratio of the repeating units derived from the monomer represented by formula (I) to the total of the repeating units derived from the monomer represented by formula (I) and the repeating units derived from the monomer represented by formula (II) is 99 mol % to 51 mol %.

3. The copolymer further comprises a copolymer represented by the following formula (III): 【Chemistry 3】 [In the formula, R ｃ and R ｄ each independently represents a hydrogen atom or a methyl group, R e represents a linear or branched alkylene group having 1 to 5 carbon atoms, and n represents a number from 1 to 50.

4. The substrate having the ability to inhibit cell adhesion is a copolymer (P) containing a repeating unit containing a group represented by the following formula (a) and a repeating unit containing a group represented by the following formula (b): 【Chemistry 4】 [In the formula, U ａ１１ , U ａ１２ , U ｂ１１ , U ｂ１２ and U ｂ１３ each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; An － represents an anion selected from the group consisting of a halide ion, an inorganic acid ion, a hydroxide ion, and an isothiocyanate ion. The method according to any one of claims 1 to 3, wherein the coating film comprises the compound of formula (I) on at least a part of the surface thereof.

5. The method according to any one of claims 1 to 4, wherein the culturing in the step of producing a cartilage tissue mass is carried out in a medium containing agar.

6. 6. The method according to claim 5, wherein the weight-average molecular weight of the agar is 10,000 to 60,000, and the content of the agar is 0.005 (w / v)% or more and less than 2 (w / v)% of the total amount of the medium.

Images